Literature DB >> 8622161

Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor.

T Todo1, E F Adams, R Fahlbusch, T Dingermann, H Werner.   

Abstract

The authors have previously shown that meningioma-derived conditioned medium profoundly stimulates the in vitro proliferation of meningioma cells. In this paper, self mitogenic agents found in the conditioned medium-autocrine growth-stimulatory factors actually secreted by human meningioma cells-are characterized as proteins related to the B chain of platelet-derived growth factor (PDGF) and possibly to the A chain of PDGF as well. The addition to conditioned medium of a neutralizing antibody against PDGF-BB caused a significant inhibition of the conditioned medium-stimulated DNA synthesis in all three meningioma cultures studied. A similar neutralizing effect was observed with an anti-PDGF-AA antibody in one meningioma culture studied. Gel filtration chromatography of concentrated conditioned medium from two different meningiomas using a Sephadex G-100 column revealed similar profiles from both conditioned media with a major peak of mitogenic activity against meningioma cells at a molecular weight (M(r)) of approximately 32 to 36 kD, accompanied by a minor peak at approximately 22 kD. The major peak mitogenic activity was significantly reduced by addition of an anti-PDGF-BB antibody. Western blot analysis of protein extracts from five meningioma specimens was performed using a monoclonal antibody against the B chain of PGDF, and a major band of PDGF-B immunoreactivity was detected at an M(r) of approximately 19 kD in all five meningiomas under both reducing and nonreducing conditions. Exogenous human and porcine PDGFs both exhibited a significant dose-dependent stimulation of DNA synthesis in two of three and three of five meningioma cultures examined, respectively. Although not all meningiomas investigated proved to share the biological activity associated with PDGF and these results may be preliminary, it seems that the autocrine growth-stimulatory loop established by PDGF-B-related molecules plays an important functional role in meningioma cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622161     DOI: 10.3171/jns.1996.84.5.0852

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  18 in total

1.  Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Authors:  David A Reardon; Andrew D Norden; Annick Desjardins; James J Vredenburgh; James E Herndon; April Coan; John H Sampson; Sridharan Gururangan; Katherine B Peters; Roger E McLendon; Julie A Norfleet; Eric S Lipp; Jan Drappatz; Patrick Y Wen; Henry S Friedman
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

2.  Induction of smooth muscle cell-like phenotype in marrow-derived cells among regenerating urinary bladder smooth muscle cells.

Authors:  Akihiro Kanematsu; Shingo Yamamoto; Eri Iwai-Kanai; Isao Kanatani; Masaaki Imamura; Rosalyn M Adam; Yasuhiko Tabata; Osamu Ogawa
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

Review 3.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

Review 4.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

5.  Expression of TGFalpha in meningiomas.

Authors:  J Halper; C Jung; A Perry; H Suliman; M P Hill; B Scheithauer
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.

Authors:  Jeffrey J Raizer; Sean A Grimm; Alfred Rademaker; James P Chandler; Kenji Muro; Irene Helenowski; Laurie Rice; Katie McCarthy; Sandra K Johnston; Maciej M Mrugala; Marc Chamberlain
Journal:  J Neurooncol       Date:  2014-01-22       Impact factor: 4.130

7.  Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.

Authors:  Peter Horak; Adelheid Wöhrer; Marco Hassler; Johannes Hainfellner; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

8.  Phenotypic change of human cultured meningioma cells.

Authors:  R Pallini; P Casalbore; D Mercanti; N Maggiano; L M Larocca
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

Review 9.  Aberrant signaling pathways in meningiomas.

Authors:  Brian T Ragel; Randy L Jensen
Journal:  J Neurooncol       Date:  2010-09-14       Impact factor: 4.130

10.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.